What is your preferred monotherapy antiplatelet agent to continue after completion of DAPT post-PCI for patients with stable ischemic heart disease?  

Would coronary disease anatomy influence your selection of which type of antiplatelet agent to continue?



Answer from: at Community Practice

Answer from: at Community Practice

Answer from: at Academic Institution

Answer from: at Community Practice
Comments
at Langhorne Cardiology Consultants Inc
Completely agree with Dr. @Collins. Most surgeons ...
Sign in or Register to read more

Answer from: at Community Practice